Tricida (NASDAQ:TCDA – Get Rating) is scheduled to be releasing its earnings data after the market closes on Monday, August 8th. Analysts expect Tricida to post earnings of ($0.52) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Tricida (NASDAQ:TCDA – Get Rating) last posted its quarterly earnings data on Tuesday, May 10th. The company reported ($0.51) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.64) by $0.13. On average, analysts expect Tricida to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Tricida Price Performance
TCDA opened at $10.86 on Friday. The stock has a fifty day simple moving average of $9.74 and a two-hundred day simple moving average of $9.41. The company has a current ratio of 5.12, a quick ratio of 5.12 and a debt-to-equity ratio of 584.92. The company has a market cap of $601.92 million, a price-to-earnings ratio of -3.76 and a beta of 0.68. Tricida has a 12-month low of $3.80 and a 12-month high of $12.45.
Insiders Place Their Bets
Hedge Funds Weigh In On Tricida
Several institutional investors and hedge funds have recently modified their holdings of TCDA. Cresset Asset Management LLC bought a new position in shares of Tricida during the first quarter valued at $1,002,000. Jane Street Group LLC increased its holdings in shares of Tricida by 355.3% during the first quarter. Jane Street Group LLC now owns 109,941 shares of the company’s stock valued at $904,000 after acquiring an additional 85,796 shares in the last quarter. Wellington Management Group LLP increased its holdings in shares of Tricida by 39.1% during the first quarter. Wellington Management Group LLP now owns 219,143 shares of the company’s stock valued at $1,801,000 after acquiring an additional 61,652 shares in the last quarter. Citigroup Inc. increased its holdings in shares of Tricida by 141.3% during the first quarter. Citigroup Inc. now owns 96,581 shares of the company’s stock valued at $794,000 after acquiring an additional 56,559 shares in the last quarter. Finally, Ensign Peak Advisors Inc bought a new position in shares of Tricida during the first quarter valued at $291,000. 79.28% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, The Goldman Sachs Group decreased their price objective on Tricida from $22.00 to $16.00 and set a “buy” rating for the company in a report on Tuesday, May 24th.
Tricida Company Profile
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.
Further Reading
- Get a free copy of the StockNews.com research report on Tricida (TCDA)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Why Apple Could Be At All-Time Highs By Year End
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.